6 days Ago By ABMN Staff
Vanguard Group Inc. lowered its holdings in NovoCure Limited ( NASDAQ:NVCR – Free Report ) by 0.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission.
The firm owned 11,796,109 shares of the medical equipment provider’s stock after selling 48,499 shares during the period. Vanguard Group Inc. owned 10.
90% of NovoCure worth $351,524,000 as of its most recent SEC filing. Several other hedge funds have also modified their holdings of the stock. LPL Financial LLC purchased a new stake in NovoCure during the 4th quarter worth $830,000.
KLP Kapitalforvaltning AS purchased a new position in NovoCure in the fourth quarter valued at about $644,000. Teacher Retirement System of Texas acquired a new stake in NovoCure during the 4th quarter valued at approximately $1,766,000. Xponance Inc.
purchased a new stake in NovoCure during the 4th quarter worth approximately $231,000. Finally, Cibc World Markets Corp acquired a new position in shares of NovoCure in the 4th quarter valued at approximately $297,000. 84.
61% of the stock is owned by institutional investors and hedge funds. Analysts Set New Price Targets Several equities analysts recently issued reports on NVCR shares. Wedbush restated a “neutral” rating and set a $29.
00 price objective on shares of NovoCure in a research note on Monday, January 13th. StockNews.com lowered NovoCure from a “hold” rating to a “sell” rating in a research report on Saturday, March 29th.
Piper Sandler increased their price target on NovoCure from $28.00 to $42.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th.
Finally, HC Wainwright reaffirmed a “buy” rating and issued a $38.00 price objective on shares of NovoCure in a report on Tuesday, January 14th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company.
According to data from MarketBeat, NovoCure has a consensus rating of “Moderate Buy” and a consensus price target of $35.80. NovoCure Stock Performance NASDAQ:NVCR opened at $16.
98 on Friday. The firm has a market cap of $1.87 billion, a price-to-earnings ratio of -12.
13 and a beta of 0.65. NovoCure Limited has a twelve month low of $11.
70 and a twelve month high of $34.13. The company has a current ratio of 1.
49, a quick ratio of 1.44 and a debt-to-equity ratio of 0.27.
The company has a 50-day moving average of $20.99 and a 200-day moving average of $21.61.
NovoCure ( NASDAQ:NVCR – Get Free Report ) last issued its earnings results on Thursday, February 27th. The medical equipment provider reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.
34) by ($0.27). NovoCure had a negative return on equity of 41.
48% and a negative net margin of 25.93%. The company had revenue of $161.
27 million during the quarter, compared to analyst estimates of $161.30 million. Analysts forecast that NovoCure Limited will post -1.
3 earnings per share for the current fiscal year. NovoCure Company Profile ( Free Report ) NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua.
Featured Articles Receive News & Ratings for NovoCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure and related companies with MarketBeat.com's FREE daily email newsletter ..
_0.jpg?itok=Jn8RJQZW)
